MyFinsight
Home
Blog
About
1-svg
Royalty Pharma plc (RPRX)
1-svg
Royalty Pharma plc (RPRX)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Cash collections from financial ...
Distributions from equity method...
Other royalty cash collections
Others
Negative Cash Flow Breakdown
Acquisitions of financial royalt...
Interest paid
Dividends to shareholders
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Cash collections from financial royalty assets
915,598
916,130
882,358
726,525
Cash collections from intangible royalty assets
3,773
39
264
240
Other royalty cash collections
33,616
29,104
29,107
24,051
Distributions from equity method investees
3,722
0
0
0
Interest received
6,497
6,373
7,248
8,662
Development-stage funding payments
25,500
50,500
50,500
351,000
Payments for operating and professional costs
36,251
58,242
34,175
94,025
Payments for employee epas
9,696
9,075
1,695
173
Interest paid
173,526
6,681
129,992
796
Net cash provided by operating activities
718,233
827,148
702,615
363,984
Acquisition of businesses, net of cash acquired
-
0
226
74,190
Distributions from equity method investees
42,306
4,994
905
62,988
Investments in equity method investees
-
0
0
0
Purchases of equity securities
22,500
54,000
0
0
Proceeds from equity securities
375
34,723
0
0
Purchases of available for sale debt securities
-
100,000
0
75,000
Proceeds from available for sale debt securities
4,320
2,880
2,880
2,880
Proceeds from sales of available for sale debt securities
0
0
0
0
Proceeds from sales and maturities of marketable securities
-
0
-
-
Acquisitions of financial royalty assets
452,366
733,685
961,873
1,114
Acquisitions of other financial assets
-
0
0
0
Milestone payments
50,000
2,713
0
218,600
Other
-
0
0
8,946
Net cash (used in)/provided by investing activities
-477,865
-847,801
-958,314
-311,982
Distributions to legacy non-controlling interests - portfolio receipts
77,973
79,149
101,907
89,220
Distributions to continuing non-controlling interests
39,880
40,756
34,281
38,605
Dividends to shareholders
104,490
94,343
95,312
93,241
Repurchases of class a ordinary shares
50,100
80,537
146,493
291,572
Contributions from legacy non-controlling interests - r&d
0
0
-219
219
Contributions from non-controlling interests - other
0
0
15
4,605
Cash acquired in connection with purchase of non-controlling interest
-
0
-
-
Proceeds from revolving credit facility
-
0
1,275,000
-
Repayment of revolving credit facility
-
0
1,275,000
-
Repayment of long-term debt
-
0
1,000,000
-
Proceeds from issuance of long-term debt, net of discount
-
0
1,954,475
0
Debt issuance costs and other
-
3,020
13,543
0
Other
-226
-1,790
0
0
Net cash used in financing activities
-272,669
-299,595
562,735
-507,814
Net change in cash and cash equivalents
-32,301
-320,248
307,036
-455,812
Cash and cash equivalents, beginning of period
618,696
1,087,720
1,087,720
1,087,720
Cash and cash equivalents, end of period
586,395
618,696
938,944
631,908
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Cash collections
from financial...
$915,598K
(10.35%↑ Y/Y)
Other royalty cash
collections
$33,616K
(5.85%↑ Y/Y)
Interest received
$6,497K
(-45.97%↓ Y/Y)
Cash collections
from intangible...
$3,773K
(2031.64%↑ Y/Y)
Distributions from equity
method investees
$3,722K
(-72.22%↓ Y/Y)
Net cash provided by
operating activities
$718,233K
(20.49%↑ Y/Y)
Canceled cashflow
$244,973K
Net change in cash
and cash...
-$32,301K
(-120.35%↓ Y/Y)
Canceled cashflow
$718,233K
Distributions from equity
method investees
$42,306K
(16.67%↑ Y/Y)
Proceeds from available
for sale debt...
$4,320K
(-65.68%↓ Y/Y)
Proceeds from equity
securities
$375K
Interest paid
$173,526K
(25.00%↑ Y/Y)
Payments for operating
and professional...
$36,251K
(-64.35%↓ Y/Y)
Development-stage funding
payments
$25,500K
(-49.50%↓ Y/Y)
Payments for employee
epas
$9,696K
Net cash (used
in)/provided by investing...
-$477,865K
(-194.83%↓ Y/Y)
Canceled cashflow
$47,001K
Net cash used in
financing activities
-$272,669K
(71.03%↑ Y/Y)
Acquisitions of financial
royalty assets
$452,366K
(42697.16%↑ Y/Y)
Milestone payments
$50,000K
(0.00%↑ Y/Y)
Purchases of equity
securities
$22,500K
(408.24%↑ Y/Y)
Dividends to shareholders
$104,490K
(9.58%↑ Y/Y)
Distributions to legacy
non-controlling interests -...
$77,973K
(139.69%↑ Y/Y)
Repurchases of class a
ordinary shares
$50,100K
(-92.93%↓ Y/Y)
Distributions to continuing
non-controlling interests
$39,880K
(-25.92%↓ Y/Y)
Other
-$226K
Buy us a coffee